gentuximab + almonertinib

Gentuximab + almonertinib is a **combination therapy under clinical investigation** for the treatment of **EGFR mutation-positive metastatic non-small cell lung cancer (NSCLC)**. Gentuximab is a monoclonal antibody, while almonertinib is a third-generation, orally available EGFR tyrosine kinase inhibitor (EGFR TKI) that irreversibly inhibits both EGFR-sensitizing and T790M resistance mutations. Almonertinib’s mechanism includes direct inhibition of EGFR signaling and modulating ABCB1 (P-glycoprotein) function to reverse multidrug resistance (MDR), restoring sensitivity to chemotherapeutic agents in ABCB1-overexpressing cancer cells. This combination is being evaluated for its safety, tolerability, and preliminary antitumor activity in patients with EGFR mutation-positive metastatic NSCLC[1][3][5][7].

Other names

gentuximab + almonertinib